Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P980053/S021

Durasphere Injectable Bulking Agent

Carbon Medical Technologies, Inc. · Decision date Mar 13, 2026

FDA DECISIONP980053/S021

What did the FDA approve?

FDA records P980053/S021 as a supplement to PMA P980053, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Mar 13, 2026.

FDA approval order statement

a change to the syringe cap of the 1 mL Durasphere device configuration
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Gastroenterology, Urology
Decision date
Mar 13, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P980053/S021
Regulatory pathway
PMA supplement
Product code
LNM
Decision code
APPR
Decision date
Mar 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE.

Product code
LNM
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P980053/S021 received

    Application receipt date recorded by FDA.

  2. P980053/S021 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P980053. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code LNM

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementJul 1, 2026FDA
Merz North America, Inc.PMA supplementJun 26, 2026FDA
Merz North America, Inc.PMA supplementMay 14, 2026FDA
Merz North America, Inc.PMA supplementMar 18, 2026FDA
COAPTITEP040047/S080
Merz North America, Inc.PMA supplementJan 13, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Carbon Medical Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1290 Hammond Rd., St. Paul, MN, 55110

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records